As mentioned before, immune infiltrates are associated with better prognoses, mainly in HER2+ and TNBC breast cancer subtypes, and, while HER2+ cancer can be treated using an anti-HER2 antibody (Trastuzumab), no targeted therapy exists for TNBC. Here, ERBB2 is linked to cancer.